Basisstatistiken
| LEI | 5299009QZVYUYO082S45 |
| CIK | 719135 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Apyx Medical Corporation
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| June 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater, Florida 33760 (Address o |
|
| June 1, 2026 |
Exhibit 1.01 CONFLICT MINERALS REPORT APYX MEDICAL CORPORATION IN ACCORDANCE WITH RULE 13P-1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 This Conflict Minerals Report (“Report”) of Apyx Medical Corporation (“APYX”) for the calendar year ended December 31, 2025 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule requires disclosure of ce |
|
| May 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 21, 2026 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization |
|
| May 21, 2026 |
EXHIBIT 99.1 New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion® Published data demonstrates visible reduction in dimpling and progressive tissue remodeling through a single-session approach Clearwater, Fla. - May 21, 2026 – Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the leader i |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 14, 2026 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization |
|
| May 14, 2026 |
EXHIBIT 99.1 Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used In Combination With Liposuction Analysis showed that liposuction followed by helium plasma RF was associated with higher patient-reported satisfaction with abdominal appearance, lower abdominoplasty and revision rates, and comparable complication rates versus conventiona |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 11, 2026 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization |
|
| May 11, 2026 |
EXHIBIT 99.1 Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™ Addition of the power liposuction capability as a second advanced liposuction modality is expected to drive even greater market demand for AYON Clearwater, Fla. - May 11, 2026 – Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the l |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 7, 2026 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization) |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX MEDICAL CORPORA |
|
| May 7, 2026 |
Apyx Medical Corporation Reports First Quarter 2026 Financial Results EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2026 Financial Results • Reported total revenue of $12.5 million in the first quarter of 2026 primarily driven by 36% growth in the Surgical Aesthetics segment • Raised total revenue guidance for FY2026 to a range of $59.0 million to $60.0 million • Management to host a conference call today at 8:00 a.m. ET CLEARWATER, FL — May 7, 2026 - |
|
| March 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 10, 2026 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizati |
|
| March 10, 2026 |
APYX MEDICAL CORPORATION SUBSIDIARIES OF REGISTRANT Exhibit 21.1 APYX MEDICAL CORPORATION SUBSIDIARIES OF REGISTRANT SUBSIDIARY NAME STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Apyx Bulgaria EOOD Bulgaria Apyx China Holding Corp. Delaware Apyx SY Medical Devices (NINGBO) Co., LTD. China |
|
| March 10, 2026 |
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results EXHIBIT 99.1 Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results • Reported record total revenue of $19.2 million in the fourth quarter of 2025 • Scaling U.S. commercial launch of AYON Body Contouring SystemTM (AYON) to meet strong market demand • Expect FY2026 total revenue in the range of $57.5 million to $58.5 million • Management to host a conference call today |
|
| March 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX ME |
|
| January 12, 2026 |
EXHIBIT 99.1 Apyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue Results Surgical Aesthetics revenue increased approximately 38% year-over-year in the fourth quarter of 2025, including an increase of approximately 51% in the U.S. following the launch of AYON CLEARWATER, FL — January 12, 2026 - Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 12, 2026 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiza |
|
| December 12, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF APYX MEDICAL CORPORATION Pursuant to § 242 of the General Corporation Law of the State of Delaware The undersigned, being the Chief Executive Officer of Apyx Medical Corporation, a corporation organized under the laws of the State of Delaware (the “Corporation”), hereby certifies: 1. The original Certificate of Incorporation o |
|
| December 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 8, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiza |
|
| December 1, 2025 |
Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) APYX MEDICAL CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, par value $0. |
|
| December 1, 2025 |
APYX MEDICAL CORPORATION INDENTURE Dated as of __________, 20___ TABLE OF CONTENTS Exhibit 4.5 APYX MEDICAL CORPORATION INDENTURE Dated as of , 20 TABLE OF CONTENTS Page No. ARTICLE I DEFINITIONS 1 Section 1.01. Definitions 2 ARTICLE II FORMS OF SECURITIES 9 Section 2.01. Terms of the Securities 9 Section 2.02. Form of Trustee’s Certificate of Authentication 9 ARTICLE III THE DEBT SECURITIES 10 Section 3.01. Amount; Issuable in Series 10 Section 3.02. Denominations 13 Section 3. |
|
| December 1, 2025 |
As filed with the Securities and Exchange Commission on December 1, 2025 As filed with the Securities and Exchange Commission on December 1, 2025 Registration No. |
|
| November 19, 2025 |
Apyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock Exhibit 99.2 Apyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock CLEARWATER FL, November 18, 2025 —Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the pricing of its previously announced underwritten public off |
|
| November 19, 2025 |
Apyx Medical Corporation Announces Proposed Public Offering of Common Stock Exhibit 99.1 Apyx Medical Corporation Announces Proposed Public Offering of Common Stock CLEARWATER FL, November 17, 2025 —Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that it is commencing an underwritten public offering of shares of its common |
|
| November 19, 2025 |
Exhibit 1.1 2,762,431 SHARES of Common Stock and 0 PRE-FUNDED Warrants of APYX MEDICAL CORPORATION UNDERWRITING AGREEMENT November 18, 2025 Lucid Capital Markets, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Lucid Capital Markets, LLC 570 Lexington Avenue, 40th Floor New York, New York 10022 Ladies and Gentlemen: The undersigned, Apyx Medical Corpor |
|
| November 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 17, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiz |
|
| November 18, 2025 |
APYX MEDICAL CORPORATION 2,762,431 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-268532 PROSPECTUS SUPPLEMENT (To Prospectus dated December 2, 2022) APYX MEDICAL CORPORATION 2,762,431 Shares of Common Stock We are offering 2,762,431 shares of our common stock, par value $0.001 per share (the “Common Stock”) to certain institutional investors, pursuant to this prospectus supplement and the accompanying prospectus. |
|
| November 17, 2025 |
Subject to completion, dated November [●], 2025 Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-268532 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and not soliciting an offer to buy these securities, in |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX MEDICAL COR |
|
| November 6, 2025 |
Apyx Medical Corporation Reports Third Quarter 2025 Financial Results EXHIBIT 99.1 Apyx Medical Corporation Reports Third Quarter 2025 Financial Results • Initiated full U.S. commercial launch of AYON Body Contouring System™ (AYON) at end of Q3 2025, with demand for pre-orders exceeding expectations • Submitted new 510(k) for AYON for device label expansion to include power liposuction • Increased total revenue guidance for FY2025 to a range of $50.5 million to $52. |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 6, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiza |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 7, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizati |
|
| August 7, 2025 |
Apyx Medical Corporation Reports Second Quarter 2025 Financial Results EXHIBIT 99.1 Apyx Medical Corporation Reports Second Quarter 2025 Financial Results • Successfully launched AYON Body Contouring System™ to key surgeons in critical geographies; plan for commercial launch in September 2025 • Initiated commercial sales of Renuvion® in China with strong clinical interest and completed initial procedures • Based on pre-sales of AYON, the Company increased its total r |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX MEDICAL CORPORAT |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 7, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizati |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ☒ Definitive Proxy State |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ☐ Definitive Proxy State |
|
| May 30, 2025 |
Exhibit 1.01 CONFLICT MINERALS REPORT APYX MEDICAL CORPORATION IN ACCORDANCE WITH RULE 13P-1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 This Conflict Minerals Report (“Report”) of Apyx Medical Corporation (“APYX”) for the calendar year ended December 31, 2024 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule requires disclosure of ce |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater, Florida 33760 (Address o |
|
| May 13, 2025 |
EXHIBIT 99.1 Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™ The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second half of 2025 Clearwater, Fla. - May 13, 2025 |
|
| May 13, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 13, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization |
|
| May 8, 2025 |
Apyx Medical Corporation Reports First Quarter 2025 Financial Results EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2025 Financial Results • Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last year • U.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last year • Preparing for a planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX MEDICAL CORPORA |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 8, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization) |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 29, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizati |
|
| April 29, 2025 |
EXHIBIT 99.1 APYX MEDICAL CORPORATION ANNOUNCES TWO PEER-REVIEWED PUBLICATIONS ON THE USE OF RENUVION IN ABDOMINAL BODY CONTOURING PROCEDURES Two studies report favorable clinical outcomes and safety data for Renuvion® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin Rapid weight loss due to GLP-1 drugs expected to drive growth in patients seeking |
|
| March 13, 2025 |
Insider Trading Policy, included in Exhibit 14 EXHIBIT 14 Code of Business Conduct and Ethics (excerpt from Employee Handbook March 2025) INTRODUCTION The Board of Directors of Apyx Medical Corporation (“Apyx” or the “Company”) has adopted this Code of Business Conduct and Ethics (the "Code") in order to: ● promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest; ● promote full, fair, accu |
|
| March 13, 2025 |
Exhibit 21.1 APYX MEDICAL CORPORATION SUBSIDIARIES OF REGISTRANT SUBSIDIARY NAME STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Apyx Bulgaria EOOD Bulgaria Apyx China Holding Corp. Delaware Apyx SY Medical Devices (NINGBO) Co., LTD. China |
|
| March 13, 2025 |
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2024 Financial Results EXHIBIT 99.1 Apyx Medical Corporation Reports Fourth Quarter and Full Year 2024 Financial Results • The number of single-use handpiece units shipped in Q4 2024 exceeded expectations, increasing 5% overall and 20% in the U.S. compared to the same period last year • Submitted a 510(k) premarket notification to the U.S. FDA for the AYON™ Body Contouring System ahead of schedule and preparing for a pl |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX ME |
|
| March 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 13, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizati |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 31, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiza |
|
| February 6, 2025 |
Employment Agreement, effective as of January 28, 2025, by and between the Company and Shawn Roman. Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, effective as of January 28, 2025 (the “Effective Date”), is hereby entered into by and between Apyx Medical Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”) and Shawn Roman ( “Executive”). WITNESSETH: WHEREAS, the Company agrees to employ Executive and Executive agrees to be employ |
|
| January 13, 2025 |
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results EXHIBIT 99.1 Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results Advanced Energy revenue increase by more than 25% quarter-over-quarter in Q4 2024 Clearwater, Fla. — January 13, 2025 - Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 13, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiza |
|
| January 6, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 6, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizat |
|
| January 6, 2025 |
EXHIBIT 99.1 Apyx Medical Corporation Submits 510(k) Premarket Notification to the U.S. Food and Drug Administration for the AYON Body Contouring System™ Focusing on advancing body contouring by providing the first all-in-one platform for the surgical suite Clearwater, Fla. — January 6, 2025 - Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietar |
|
| November 8, 2024 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT APYX MEDICAL CORPORATION Warrant Shares: Issue Date: November [●], 2024 Initial Exercise Date: November [●], 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set |
|
| November 8, 2024 |
Amendment No.1 to Credit Agreement and Guaranty, dated November 7, 2024 Exhibit 10.1 Execution Version AMENDMENT NO. 1 TO CREDIT AGREEMENT AND GUARANTY This AMENDMENT NO. 1 TO CREDIT AGREEMENT AND GUARANTY, dated as of November 7, 2024 (this “Amendment”), is among Apyx Medical Corporation, a Delaware corporation (the “Borrower”), the Subsidiary Guarantors party hereto, the Lenders party hereto and Perceptive Credit Holdings IV, LP, as administrative agent for the Lend |
|
| November 8, 2024 |
Securities Purchase Agreement, dated November 7, 2024. Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 7, 2024, between Apyx Medical Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| November 8, 2024 |
Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering Exhibit 99.2 Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering CLEARWATER, FL — November 8, 2024 - Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced it has entered into a definitive purchase agreement with Nant |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX MEDICAL COR |
|
| November 8, 2024 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-268532 Prospectus Supplement (To Prospectus dated December 2, 2022) APYX MEDICAL CORPORATION 3,000,000 Shares of Common Stock 2,934,690 Pre-Funded Warrants to Purchase up to 2,934,690 Shares of Common Stock 2,934,690 Shares of Common Stock underlying the Pre-Funded Warrants We are offering 3,000,000 shares of our common stock, par val |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 4, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiza |
|
| November 8, 2024 |
EXHIBIT 99.1 Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook ● Strengthened balance sheet with a common stock registered direct offering with gross proceeds of approximately $7.0 million; and amended revenue covenants for the Company’s credit agreement with Perceptive ● Announces cost sa |
|
| October 31, 2024 |
EX-99.1 2 ex991to13g14118002103124.htm Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated October 31, 2024 with respect to the Common Stock, $0.001 par value, of Apyx Medical Corporation and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with |
|
| October 31, 2024 |
APYX / Apyx Medical Corporation / Archon Capital Management LLC - SCHEDULE 13G Passive Investment SC 13G 1 sc13g1411800210312024.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Apyx Medical Corporation (Name of Issuer) Common Stock, $0.001 par value (Title of Class of |
|
| October 15, 2024 |
APYX / Apyx Medical Corporation / ROYCE & ASSOCIATES LP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information statement pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No.2) Apyx Medical Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 03837C106 (CUSIP Number) Date of Event Which Requires Filing of this Statement: September 30, 2024 *The remainder |
|
| August 12, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 8, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizati |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX MEDICAL CORPORAT |
|
| August 8, 2024 |
EXHIBIT 99.1 Apyx Medical Corporation Reports Second Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook CLEARWATER, FL — August 8, 2024 - Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported financial results for its second q |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 8, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizati |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ý Definitive Proxy State |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater, Florida 33760 (Address o |
|
| May 31, 2024 |
Exhibit 1.01 CONFLICT MINERALS REPORT APYX MEDICAL CORPORATION IN ACCORDANCE WITH RULE 13P-1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 This Conflict Minerals Report (“Report”) of Apyx Medical Corporation (“APYX”) for the calendar year ended December 31, 2023 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule requires disclosure of ce |
|
| May 9, 2024 |
Letter Agreement, dated May 7, 2024, between Apyx Medical Corporation and Stavros G. Vizirgianakis Execution Version\ Exhibit 10.1 APYX MEDICAL CORPORATION. 5115 Ulmerton Road Clearwater, Florida 33760 May 7, 2024 Via Email Mr. Stavros G. Vizirgianakis 99 Boulevard du Jardin Exotique, Monaco 98000 Dear Mr. Vizirgianakis: The Board of Directors (the “Board”) of Apyx Medical Corporation (the “Company”) has considered appointing you as a director (in such capacity, you are referred to herein as th |
|
| May 9, 2024 |
APYX / Apyx Medical Corporation / Vizirgianakis Stavros G. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Apyx Medical Corporation (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 03837C106 (CUSIP Number) Stavros G. Vizirgianakis c/o Amy E. Culbert, Esq. Fox Rothschild LLP City Center 33 South Sixth Street, Suite 3600 Minneapoli |
|
| May 9, 2024 |
EXHIBIT 99.1 Apyx Medical Corporation Announces Board Leadership Transition Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman CLEARWATER, FL — May 9, 2024 - Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma a |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 7, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization) |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX MEDICAL CORPORA |
|
| May 9, 2024 |
EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2024 Financial Results; Reaffirms Full Year 2024 Financial Outlook CLEARWATER, FL — May 9, 2024 - Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its first quarter ended |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 9, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization) |
|
| April 5, 2024 |
APYX / Apyx Medical Corporation / Archon Capital Management LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Apyx Medical Corporation (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 03837C106 (CUSIP Number) MR. Constantinos J. Chr |
|
| April 5, 2024 |
EX-99.1 2 ex991to13d00322001040424.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.001 par va |
|
| April 1, 2024 |
APYX / Apyx Medical Corporation / Vizirgianakis Stavros G. - SC 13D Activist Investment SC 13D 1 ef20025615sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Apyx Medical Corporation (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 03837C106 (CUSIP Number) Stavros G. Vizirgianakis c/o Amy E. Culbert, Esq. Fox Rothschild LLP City Center 33 South |
|
| March 25, 2024 |
APYX / Apyx Medical Corporation / HIRSCHMAN ORIN Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03837C106 (CUSIP Number) March 22, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| March 21, 2024 |
Apyx Medical Corporation Clawback Policy, effective October 2, 2023 EXHIBIT 97.1 EXECUTIVE COMPENSATION CLAWBACK POLICY 1.Introduction The Board of Directors (the “Board”) of Apyx Medical Corporation (the “Company”) and its wholly owned subsidiaries have adopted this policy (this “Policy”) to provide for the recovery or “clawback” of erroneously awarded incentive-based compensation from certain executive officers in accordance with Section 10D of the Securities Ex |
|
| March 21, 2024 |
EXHIBIT 99.1 Apyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook Advanced Energy Sales increased 15% year-over-year and 23% quarter-over-quarter in the fourth quarter; increased 18% year-over-year in 2023 CLEARWATER, FL — March 21, 2024 - Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufac |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX MEDICAL CORPORATION |
|
| March 21, 2024 |
APYX MEDICAL CORPORATION SUBSIDIARIES OF REGISTRANT SUBSIDIARY NAME STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Apyx Bulgaria EOOD Bulgaria Apyx China Holding Corp. Delaware Apyx SY Medical Devices (NINGBO) Co., LTD. China |
|
| March 21, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 21, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizati |
|
| February 21, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 21, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiz |
|
| February 21, 2024 |
EXHIBIT 99.1 Apyx Medical Corporation Announces Renuvion to be Featured in Educational Sessions at the American Academy of Cosmetic Surgery (AACS) Scientific Meeting Presentation hosted by Dr. Michael Kluska to feature the results of a retrospective clinical study comparing the use of Renuvion to a competing technology when used in conjunction with liposuction or body contouring, demonstrating sig |
|
| February 14, 2024 |
APYX / Apyx Medical Corporation / RTW INVESTMENTS, LP - APYX MEDICAL CORPORATION Passive Investment SC 13G/A 1 p24-0394sc13ga.htm APYX MEDICAL CORPORATION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Apyx Medical Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03837C106 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement |
|
| February 14, 2024 |
APYX / Apyx Medical Corporation / Divisadero Street Capital Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
APYX / Apyx Medical Corporation / PURA VIDA INVESTMENTS, LLC Passive Investment SC 13G/A 1 apyx13g.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2)* APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03837C106 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropri |
|
| February 13, 2024 |
APYX / Apyx Medical Corporation / Archon Capital Management LLC Passive Investment SC 13G/A 1 d1096421913g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 03837C106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| February 7, 2024 |
APYX / Apyx Medical Corporation / HIRSCHMAN ORIN Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03837C106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| February 2, 2024 |
SC 13G/A 1 apyxa320224.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Apyx Medical Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 03837c106 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropria |
|
| January 23, 2024 |
APYX / Apyx Medical Corporation / ROYCE & ASSOCIATES LP Passive Investment SC 13G/A 1 apyx.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information statement pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No.) Apyx Medical Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 03837C106 (CUSIP Number) Date of Event Which Requires Filing of this Statement: December 31, 2 |
|
| January 23, 2024 |
APYX / Apyx Medical Corporation / ROYCE & ASSOCIATES LP Passive Investment SC 13G 1 apyx.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information statement pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No.) Apyx Medical Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 03837C106 (CUSIP Number) Date of Event Which Requires Filing of this Statement: December 31, 202 |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 22, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiza |
|
| January 22, 2024 |
EXHIBIT 99.1 Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body Analysis of data from 483 patients with a total of 1,184 body areas treated found the use of Renuvion for subcutaneous soft tissue contraction following liposuction demonstrated no new or increased risks for any area of the body, |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 8, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizat |
|
| January 8, 2024 |
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results EXHIBIT 99.1 Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results CLEARWATER, FL — January 8, 2024 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended Decem |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 21, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiz |
|
| November 28, 2023 |
Employment Agreement, effective as of December 4, 2023, by and between the Company and Matthew Hill. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, effective as of December 4, 2023 (the “Effective Date”), is hereby entered into by and between Apyx Medical Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”) and Matthew Hill (the “Executive”). |
|
| November 28, 2023 |
Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer CLEARWATER, FL — November 28, 2023 - Apyx Medical Corporation (Nasdaq:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. |
|
| November 16, 2023 | ||
| November 16, 2023 |
As filed with the Securities and Exchange Commission on November 16, 2023 As filed with the Securities and Exchange Commission on November 16, 2023 Registration No. |
|
| November 16, 2023 | ||
| November 16, 2023 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) APYX MEDICAL CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| November 16, 2023 |
As filed with the Securities and Exchange Commission on November 16, 2023 As filed with the Securities and Exchange Commission on November 16, 2023 Registration No. |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 9, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiza |
|
| November 16, 2023 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) APYX MEDICAL CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 8, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 00-31885 11-2644611 (State or other jurisdiction of incorporation or organizat |
|
| November 9, 2023 |
Exhibit 99.1 Apyx Medical Corporation Announces New Debt Facility with Perceptive Advisors New facility includes senior, secured term loans of up to $45 million CLEARWATER, FL — November 9, 2023 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that the Company and |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX MEDICAL COR |
|
| November 9, 2023 |
Warrant to Purchase Stock, dated Exhibit 4.1 WARRANT CERTIFICATE THIS WARRANT certificate AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT certificate HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUC |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 9, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiza |
|
| November 9, 2023 |
EXHIBIT 99.1 Apyx Medical Corporation Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook Advanced Energy Sales increased 39% year-over-year in Q3 CLEARWATER, FL — November 9, 2023 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reporte |
|
| November 9, 2023 |
Exhibit 10.1 CREDIT AGREEMENT AND GUARANTY dated as of November 8, 2023 between APYX MEDICAL CORPORATION as the Borrower, THE SUBSIDIARY GUARANTORS FROM TIME TO TIME PARTY HERETO, as the Subsidiary Guarantors, THE LENDERS FROM TIME TO TIME PARTY HERETO, as the Lenders, and PERCEPTIVE CREDIT HOLDINGS IV, LP, as the Initial Lender and Administrative Agent U.S. $45,000,000 Table of Contents Page SECT |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 10, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizatio |
|
| August 14, 2023 |
APYX / Apyx Medical Corp / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03837C106 (CUSIP Number) August 11, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATIO |
|
| August 10, 2023 |
EXHIBIT 99.1 Apyx Medical Corporation Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Financial Outlook Advanced Energy Sales increased 40% year-over-year in Q2 CLEARWATER, FL — August 10, 2023 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today repor |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 10, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizatio |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ý Definitive Proxy State |
|
| June 13, 2023 |
APYX / Apyx Medical Corp / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03837C106 (CUSIP Number) June 6, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| May 31, 2023 |
a2022conflictxmineralsx Exhibit 1.01 CONFLICT MINERALS REPORT APYX MEDICAL CORPORATION IN ACCORDANCE WITH RULE 13P-1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 This Conflict Minerals Report (“Report”) of Apyx Medical Corporation (“APYX”) for the calendar year ended December 31, 2022 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule r |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater, Florida 10577 (Address of |
|
| May 19, 2023 |
APYX / Apyx Medical Corp / Divisadero Street Capital Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Apyx Medical Corporation (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03837C106 (CUSIP Number) May 18, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| May 12, 2023 |
APYX / Apyx Medical Corp / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03837C106 (CUSIP Number) May 11, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| May 11, 2023 |
EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook CLEARWATER, FL — May 11, 2023 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its first quarter ended March 31, 202 |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 11, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATI |
|
| April 18, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 13, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization |
|
| April 18, 2023 |
First Amendment to Purchase and Sale Agreement, dated April 12, 2023 psaamendment First Amendment to Apyx – VK PSA 1 ACTIVE 686727528v2 First Amendment to Purchase and Sale Agreement (Inspection Period, Closing Extension) BY THIS FIRST AMENDMENT TO PURCHASE AND SALE AGREEMENT (INSPECTION PERIOD, CLOSING DATE) (this “First Amendment”), is made effective as of the 12th day of April 2023, by and between VK ACQUISTIONS VI, LLC, a Delaware limited liability company (“Purchaser”), and APYX MEDICAL CORPORATION, a Delaware corporation (“Seller”), in consideration of the premises and the mutual covenants set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, agree as follows: 1. |
|
| March 16, 2023 |
APYX MEDICAL CORPORATION SUBSIDIARIES OF REGISTRANT SUBSIDIARY NAME STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Apyx Bulgaria EOOD Bulgaria Apyx China Holding Corp. Delaware Apyx SY Medical Devices (NINGBO) Co., LTD. China |
|
| March 16, 2023 |
EXHIBIT 99.1 Apyx Medical Corporation Reports Fourth Quarter and Full Year 2022 Financial Results; Introduces Full Year 2023 Financial Outlook CLEARWATER, FL — March 16, 2023 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its fourth quarter a |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 16, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATION (E |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 14, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization |
|
| March 15, 2023 |
Purchase and Sale Agreement, dated March 14, 2023 EXECUTION VERSION PURCHASE AND SALE AGREEMENT THIS PURCHASE AND SALE AGREEMENT (the “Agreement”) is made and entered into as of this 13th day of March, 2023 (the “Effective Date”), by and between Apyx Medical Corporation, a Delaware corporation (the “Seller”) and VK Acquisitions VI, LLC, a Delaware limited liability company (the “Purchaser”). |
|
| March 15, 2023 |
Form of Single Tenant Industrial Building Lease SINGLE TENANT INDUSTRIAL BUILDING LEASE Between VK , LLC, Landlord, and APYX MEDICAL CORPORATION, Tenant Dated: , 2023 5115 ULMERTON ROAD, CLEARWATER, FLORIDA 33760 TABLE OF CONTENTS Article 1 BASIC LEASE PROVISIONS 1 2 GRANT OF LEASE; TERM; POSSESSION 3 3 BASE RENT 3 4 IMPOSITIONS 4 5 USE OF PREMISES 5 6 UTILITIES AND SERVICES 5 7 CONDITION OF PREMISES; COMPLIANCE WITH LEGAL REQUIREMENTS 6 8 RETU |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 17, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizat |
|
| February 24, 2023 |
EXHIBIT 99.1 Apyx Medical Corporation Announces New Five-Year Credit Agreement with MidCap Financial Facility includes a senior, secured term loan of up to $25 million and a revolving line of credit of up to $10 million CLEARWATER, FL — February 21, 2023 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed |
|
| February 24, 2023 |
Warrant to Purchase Stock, dated February 17, 2023 Exhibit 10.3 Execution Version THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE S |
|
| February 24, 2023 |
Credit, Security and Guaranty Agreement, dated February 17, 2023 Exhibit 10.1 Execution Version CREDIT, SECURITY AND GUARANTY AGREEMENT dated as of February 17, 2023 by and among APYX MEDICAL CORPORATION, as Borrower and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and APYX CHINA HOLDING CORP. as Guarantor and any additional guarantor that hereafter becomes party hereto, each as Guarantor, and col |
|
| February 24, 2023 |
Fee Letter, dated February 17, 2023 Exhibit 10.2 Execution Version c/o MidCap Financial Services, LLC, as servicer 7255 Woodmont Avenue, Suite 300 Bethesda, Maryland 20814 www.midcapfinancial.com February 17, 2023 Apyx Medical Corporation 5115 Ulmerton Rd. Clearwater, FL 33760 Attn: Tara Semb Re: Credit, Security and Guaranty Agreement with Apyx Medical Corporation and Apyx China Holding Corp. Ladies and Gentlemen: This fee letter ( |
|
| February 14, 2023 |
APYX / Apyx Medical Corp / PURA VIDA INVESTMENTS, LLC Passive Investment SC 13G/A 1 apyx.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1)* APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03837C106 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate |
|
| February 13, 2023 |
APYX / Apyx Medical Corp / Archon Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Apyx Medical Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 03837c106 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| January 10, 2023 |
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results EXHIBIT 99.1 Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results CLEARWATER, FL — January 10, 2023 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended Dece |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 10, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 11-2644611 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater, |
|
| November 30, 2022 |
United States securities and exchange commission logo November 29, 2022 Charles D. |
|
| November 30, 2022 |
November 30, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| November 23, 2022 |
APYX / Apyx Medical Corp / PURA VIDA INVESTMENTS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03837C106 (CUSIP Number) November 16, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| November 22, 2022 |
Exhibit 4.1 APYX MEDICAL CORPORATION INDENTURE Dated as of , 20 ii TABLE OF CONTENTS Page No. ARTICLE I DEFINITIONS 1 Section 1.01. Definitions 2 ARTICLE II FORMS OF SECURITIES 9 Section 2.01. Terms of the Securities 9 Section 2.02. Form of Trustee?s Certificate of Authentication 9 ARTICLE III THE DEBT SECURITIES 10 Section 3.01. Amount; Issuable in Series 10 Section 3.02. Denominations 13 Section |
|
| November 22, 2022 |
APYX MEDICAL CORPORATION EQUITY DISTRIBUTION AGREEMENT November 22, 2022 PIPER SANDLER & CO. |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 11-2644611 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater, FL 33760 (727) 384-2323 (Address |
|
| November 22, 2022 |
EX-FILING FEES 2 filingfeetable.htm EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Apyx Medical Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggreg |
|
| November 21, 2022 |
APYX / Apyx Medical Corp / Archon Capital Management LLC Passive Investment apUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 10, 2022 |
EXHIBIT 99.1 Apyx Medical Corporation Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook CLEARWATER, FL — November 10, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its third quarter ended Septembe |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 10, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizat |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPO |
|
| August 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 11, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizatio |
|
| August 11, 2022 |
EXHIBIT 99.1 Apyx Medical Corporation Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook CLEARWATER, FL ? August 11, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion?, today reported financial results for its second quarter ended June 30, |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 11, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizatio |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATIO |
|
| July 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 18, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) |
|
| July 18, 2022 |
1 Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion? to Improve Appearance of Lax (Loose) Skin CLEARWATER, FL ? July 18, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion?, today announced it has received 510(k) clearance from the U. |
|
| July 8, 2022 |
APYX / Apyx Medical Corp / BlackRock Inc. Passive Investment us03837c1062070822.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) APYX MEDICAL CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 03837C106 - (CUSIP Number) June 30, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| June 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Proxy State |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 June 7, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) |
|
| May 27, 2022 |
EX-1.01 2 conflictmineralsxreport.htm EX-1.01 Exhibit 1.01 CONFLICT MINERALS REPORT APYX MEDICAL CORPORATION IN ACCORDANCE WITH RULE 13P-1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 This Conflict Minerals Report (“Report”) of Apyx Medical Corporation (“APYX”) for the calendar year ended December 31, 2021 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (t |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater, Florida 10577 (Address of |
|
| May 26, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 26, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) |
|
| May 26, 2022 |
1 Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion? Cosmetic Technology in Dermal Resurfacing Procedures CLEARWATER, FL ? May 26, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion? and J- Plasma? in surgical markets, today announced it has received 510(k) clearance from the U. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATI |
|
| May 12, 2022 |
EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook Advanced Energy sales increased 41% year-over-year in Q1 CLEARWATER, FL ? May 12, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion? and J-Pla |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 12, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) |
|
| April 4, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 4, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) |
|
| April 4, 2022 |
Apyx Medical Corporation Announces FDA 510(k) Submission with Clinical Study Support for the Use of the Renuvion? APR Handpiece for Aesthetic Procedures to Improve Appearance of Lax Skin CLEARWATER, FL ? April 4, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion? in the cosmetic surgery market and J-Plasma? in the hospital surgical market, today announced it has submitted a 510(k) premarket notification (?510(k) submission?) to the U. |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 1, 2019 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATION (E |
|
| March 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 17, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization |
|
| March 17, 2022 |
EXHIBIT 99.1 Apyx Medical Corporation Reports Fourth Quarter and Full Year 2021 Financial Results; Introduces Full Year 2022 Financial Outlook Advanced Energy Sales increased 52% year-over-year in Q4; up 94% year-over-year in 2021 CLEARWATER, FL ? March 17, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Tech |
|
| March 17, 2022 |
APYX MEDICAL CORPORATION SUBSIDIARIES OF REGISTRANT SUBSIDIARY NAME STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Apyx Bulgaria EOOD Bulgaria Apyx China Holding Corp. Delaware |
|
| March 14, 2022 |
Apyx Medical Corporation Notified of Pending FDA Medical Device Safety Communication Related to its Advanced Energy Products CLEARWATER, FL ? March 14, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion? in the cosmetic surgery market and J-Plasma? in the hospital surgical market, today announced it has been notified by the U. |
|
| March 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 14, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization |
|
| February 14, 2022 |
APYX / Apyx Medical Corp / Archon Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
APYX / Apyx Medical Corp / RTW INVESTMENTS, LP - APYX MEDICAL CORPORATION Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Apyx Medical Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03837C106 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursu |
|
| February 1, 2022 |
APYX / Apyx Medical Corp / BlackRock Inc. Passive Investment us03837c1062013122.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) APYX MEDICAL CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 03837C106 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Apyx Medical Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 03837c106 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| January 10, 2022 |
1 Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2021 Revenue Results Advanced Energy Sales of approximately $14. |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 10, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPO |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 11, 2021 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizat |
|
| November 12, 2021 |
EXHIBIT 99.1 Apyx Medical Corporation Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 88% year-over-year in Q3 CLEARWATER, FL ? November 11, 2021 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion? in the cosmeti |
|
| August 30, 2021 |
Apyx Medical Corporation Announces Appointment of Wendy Levine to the Company?s Board of Directors CLEARWATER, FL ? August 30, 2021 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion? in the cosmetic surgery market and J-Plasma? in the hospital surgical market, announced today that the Company has appointed Wendy Levine to the Board of Directors, effective August 25, 2021. |
|
| August 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 24, 2021 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizatio |
|
| August 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Apyx Medical Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 03837c106 (CUSIP Number) August 13, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Ru |
|
| August 18, 2021 |
As filed with the Securities and Exchange Commission on August 18, 2021 As filed with the Securities and Exchange Commission on August 18, 2021 Registration No. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATIO |
|
| August 12, 2021 |
EXHIBIT 99.1 Apyx Medical Corporation Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 248% year-over-year in Q2 CLEARWATER, FL ? August 12, 2021 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion? in the cosmeti |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 12, 2021 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizatio |
|
| August 9, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 6, 2021 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization |
|
| July 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Amendment No. 1 Filed by the Registrant ? Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) o Defini |
|
| June 25, 2021 |
4.1 Apyx Medical Corporation 20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Proxy State |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater, Florida 10577 (Address of |
|
| May 26, 2021 |
Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| May 12, 2021 |
EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 92% year-over-year in Q1 CLEARWATER, FL ? MAY 12, 2021 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion? in the cosmetic sur |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 12, 2021 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATI |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATION (E |
|
| March 31, 2021 |
EXHIBIT 99.1 Apyx Medical Corporation Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Outlook Advanced Energy Sales increased 44% year-over-year in Q4 CLEARWATER, FL — MARCH 31, 2021 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Re |
|
| March 31, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 31, 2021 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization |
|
| March 30, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 25, 2021 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) EX-1 2 ex1.htm Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. 4 under the Securities Exchange Act of 1934, as amended, with respect to the common stock, $0.001 par value, of Apyx Medical Corporation. beneficially owned by them, together with any or all amendments thereto, when and if appropria |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 29, 2021 |
us03837c1062012821.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) APYX MEDICAL CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 03837C106 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 13, 2021 |
Apyx Medical Corporation Reports Preliminary Full Year and Fourth Quarter 2020 Revenue Results Advanced Energy Sales of approximately $9. |
|
| January 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 13, 2021 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati |
|
| November 12, 2020 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 5, 2020 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati |
|
| November 9, 2020 |
Apyx Medical Corporation Reports Third Quarter 2020 Financial Results EXHIBIT 99.1 Apyx Medical Corporation Reports Third Quarter 2020 Financial Results CLEARWATER, FL — NOVEMBER 9, 2020 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial resu |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 9, 2020 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPO |
|
| September 18, 2020 |
Charles D. Goodwin II Amended and Restated Employment Agreement amendedrestatedgoodwinem EXECUTION VERSION AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), effective as of September 17, 2020 (the “Effective Date”), by and between Apyx Medical Corporation, a corporation organized and existing under the laws of the State of Delaware (hereinafter referred to as the “Company") and Charles D. |
|
| September 18, 2020 |
Todd Hornsby Amended and Restated Employment Agreement toddhornsbyagreement EXECUTION VERSION AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), effective as of September 17, 2020 (the “Effective Date”), by and between Apyx Medical Corporation, a corporation organized and existing under the laws of the State of Delaware (hereinafter referred to as the “Company") and Todd Hornsby (hereinafter referred to as the “Executive"). |
|
| September 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 16, 2020 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organiza |
|
| September 18, 2020 |
Tara Harris Semb Amended and Restated Employment Agreement sembemploymentagreement EXECUTION VERSION AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT, effective as of September 16, 2020 (the “Effective Date”), is hereby entered into by and between Apyx Medical Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company") and Tara Harris Semb (the “Executive"). |
|
| August 21, 2020 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 17, 2020 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its Charter) Delaware 012183 11-2644611 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| August 21, 2020 |
Letter from BDO USA, LLP, dated August 20, 2020 EX-16.1 2 bdoletter.htm EXHIBIT 16.1 Tel: 813-321-6869 501 E Kennedy Blvd, Suite 910 Fax: 813-448-1886 Tampa, FL 33602 www.bdo.com August 20, 2020 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on August 17, 2020, to be filed by our former client, Apyx Medical Corp. |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 10, 2020 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizatio |
|
| August 10, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 6, 2020 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization |
|
| August 10, 2020 |
Apyx Medical Corporation Reports Second Quarter 2020 Financial Results EXHIBIT 99.1 Apyx Medical Corporation Reports Second Quarter 2020 Financial Results CLEARWATER, FL — AUGUST 10, 2020 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial resu |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATIO |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Amendment No. 1 Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) o Defini |
|
| June 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ý Definitive Proxy State |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater, Florida 10577 (Address of |
|
| June 1, 2020 |
exhibit101 Exhibit 1.01 CONFLICT MINERALS REPORT APYX MEDICAL CORPORATION IN ACCORDANCE WITH RULE 13P-1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 This Conflict Minerals Report (“Report”) of Apyx Medical Corporation (“APYX”) for the calendar year ended December 31, 2019 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). Numerous terms in this |
|
| May 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 11, 2020 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATI |
|
| May 11, 2020 |
Apyx Medical Corporation Reports First Quarter 2020 Financial Results EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2020 Financial Results CLEARWATER, FL — MAY 11, 2020 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 |
|
| March 31, 2020 |
apyxmedicalcodeofbusines CODE OF BUSINESS CONDUCT AND ETHICS (excerpt from EMPLOYEE HANDBOOK) DECEMBER 2019 Code of Business Conduct and Ethics INTRODUCTION The Board of Directors of Apyx Medical Corporation (“Apyx” or the “Company”) has adopted this Code of Business Conduct and Ethics (the "Code") in order to: promote honest and ethical conduct, including the ethical handling of actual or appar |
